Style | Citing Format |
---|---|
MLA | Sanaei M, et al.. "Effect of 5-Aza-2-Deoxy Cytidine on P16ink4a, P14arf, P15ink4b Genes Expression, Cell Viability, and Apoptosis in Plc/Prf5 and Mia Paca-2 Cell Lines." Iranian Journal of Pediatric Hematology and Oncology, vol. 9, no. 4, 2019, pp. 219-228. |
APA | Sanaei M, Kavoosi F, Mohammadi M, Khanezad M (2019). Effect of 5-Aza-2-Deoxy Cytidine on P16ink4a, P14arf, P15ink4b Genes Expression, Cell Viability, and Apoptosis in Plc/Prf5 and Mia Paca-2 Cell Lines. Iranian Journal of Pediatric Hematology and Oncology, 9(4), 219-228. |
Chicago | Sanaei M, Kavoosi F, Mohammadi M, Khanezad M. "Effect of 5-Aza-2-Deoxy Cytidine on P16ink4a, P14arf, P15ink4b Genes Expression, Cell Viability, and Apoptosis in Plc/Prf5 and Mia Paca-2 Cell Lines." Iranian Journal of Pediatric Hematology and Oncology 9, no. 4 (2019): 219-228. |
Harvard | Sanaei M et al. (2019) 'Effect of 5-Aza-2-Deoxy Cytidine on P16ink4a, P14arf, P15ink4b Genes Expression, Cell Viability, and Apoptosis in Plc/Prf5 and Mia Paca-2 Cell Lines', Iranian Journal of Pediatric Hematology and Oncology, 9(4), pp. 219-228. |
Vancouver | Sanaei M, Kavoosi F, Mohammadi M, Khanezad M. Effect of 5-Aza-2-Deoxy Cytidine on P16ink4a, P14arf, P15ink4b Genes Expression, Cell Viability, and Apoptosis in Plc/Prf5 and Mia Paca-2 Cell Lines. Iranian Journal of Pediatric Hematology and Oncology. 2019;9(4):219-228. |
BibTex | @article{ author = {Sanaei M and Kavoosi F and Mohammadi M and Khanezad M}, title = {Effect of 5-Aza-2-Deoxy Cytidine on P16ink4a, P14arf, P15ink4b Genes Expression, Cell Viability, and Apoptosis in Plc/Prf5 and Mia Paca-2 Cell Lines}, journal = {Iranian Journal of Pediatric Hematology and Oncology}, volume = {9}, number = {4}, pages = {219-228}, year = {2019} } |
RIS | TY - JOUR AU - Sanaei M AU - Kavoosi F AU - Mohammadi M AU - Khanezad M TI - Effect of 5-Aza-2-Deoxy Cytidine on P16ink4a, P14arf, P15ink4b Genes Expression, Cell Viability, and Apoptosis in Plc/Prf5 and Mia Paca-2 Cell Lines JO - Iranian Journal of Pediatric Hematology and Oncology VL - 9 IS - 4 SP - 219 EP - 228 PY - 2019 ER - |